These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2139264)

  • 1. Rapid T cell recovery after prophylactic ALG is associated with pancreas allograft rejection.
    Munn SR; Perkins JD
    Transplant Proc; 1990 Apr; 22(2):619. PubMed ID: 2139264
    [No Abstract]   [Full Text] [Related]  

  • 2. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
    Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
    [No Abstract]   [Full Text] [Related]  

  • 3. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
    Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of a tolerogenic immune balance and elimination of autoreactive B cells--two important effects of antithymocyte globulin treatment.
    Söderström T; Olausson M; Blohmé I; Enskog A; Mjörnstedt L; Wramner L; Kjellson B; Brynger H
    Transplant Proc; 1990 Aug; 22(4):1795-7. PubMed ID: 2117810
    [No Abstract]   [Full Text] [Related]  

  • 5. The successful use of repeated courses of OKT3 for hepatic allograft rejection using %T3 cells to adjust dose.
    Colonna JO; Millis JM; Martello J; Levy P; Iwaki Y; Brems JJ; Klein AS; Hiatt JR; Busuttil RW
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2247-8. PubMed ID: 2523600
    [No Abstract]   [Full Text] [Related]  

  • 6. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
    Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
    Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
    [No Abstract]   [Full Text] [Related]  

  • 7. In vivo-in vitro correlates of human rejection using flow cytometry with two-color fluorescence on peripheral blood mononuclear cells.
    Gross U; Thomas F; Matthews C; Thomas J; Cunningham P; Ritter T
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1609-10. PubMed ID: 2978885
    [No Abstract]   [Full Text] [Related]  

  • 8. Prolonged and repeated courses of OKT3 after liver transplantation.
    Colledan M; Gridelli B; Rossi G; Caccamo L; Gatti S; Bonara P; Fassati LR; Ferla G; Maggi U; Reggiani P
    Transplant Proc; 1990 Aug; 22(4):1769-71. PubMed ID: 2143859
    [No Abstract]   [Full Text] [Related]  

  • 9. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection.
    Ippoliti G; Fronterrè A
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3133-4. PubMed ID: 2523173
    [No Abstract]   [Full Text] [Related]  

  • 10. Natural killer cell subsets and alloresponsiveness in renal allograft recipients.
    Shabtai M; Waltzer WC; Pullis CK; Raisbeck AP; Malinowski K; Rapaport FT
    Transplant Proc; 1990 Aug; 22(4):1846-8. PubMed ID: 2143863
    [No Abstract]   [Full Text] [Related]  

  • 11. Flow-cytometric monitoring of ATG therapy for steroid-resistant rejection.
    Clark KR; Forsythe JL; Shenton BK; Lennard TW; Proud G; Taylor RM
    Transplant Proc; 1992 Feb; 24(1):315. PubMed ID: 1531714
    [No Abstract]   [Full Text] [Related]  

  • 12. Phenotypes of in vivo-activated T lymphocytes from a pancreas allograft.
    Binimelis J; Sutherland D; Sibley R; de Leiva A; Barbosa J
    Transplant Proc; 1987 Feb; 19(1 Pt 1):403. PubMed ID: 3274794
    [No Abstract]   [Full Text] [Related]  

  • 13. Nashville antithymocyte serum: a safe and efficacious agent for prophylaxis after heart transplantation.
    Frist WH; Merrill WH; Eastburn TE; Stewart JR; Hammon JW; Fortune DS; Guy TS; Bender HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1160-1. PubMed ID: 1846455
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
    Knight RJ; Kerman RH; Podder H; Katz SM; Van Buren CT; Kahan BD
    Transplant Proc; 2005 Mar; 37(2):1280-2. PubMed ID: 15848695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic monitoring parameters in ALG- versus non-ALG-treated renal transplant patients.
    McAlack RF; Stern S; Beizer R; Sklar L; Bannett A
    Transplant Proc; 1979 Jun; 11(2):1431-2. PubMed ID: 382532
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lymphocytic molecules implicated in rosette phenomenon. Differential effect of antilymphocyte serum on T (CD2+E2+) and B (CD2-E2+) lymphocytes].
    Ticchioni M; Bernard-Pomier G; Cassuto-Viguier E; Zoccola D; Allieri-Rosenthal MA; Vivinus M; Bernard A
    Therapie; 1992; 47(4):293-6. PubMed ID: 1494790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic analysis of CD3 + alpha/beta TCR-cells in allograft recipients and in normal lymphoid tissue.
    Schwinzer R; Schlitt HJ; Wonigeit K; Pichlmayr R
    Transplant Proc; 1989 Feb; 21(1 Pt 1):111-2. PubMed ID: 2523117
    [No Abstract]   [Full Text] [Related]  

  • 19. Expansion of a CD 3+4-8- TCR alpha/beta- T lymphocyte population in renal allograft recipients.
    Volk HD; Reinke P; Neuhaus K; Fiebig H; von Baehr R
    Transplantation; 1989 Mar; 47(3):556-8. PubMed ID: 2646785
    [No Abstract]   [Full Text] [Related]  

  • 20. Prophylactic use of the new monoclonal antibody BMA 031 in clinical kidney transplantation.
    Smely S; Weschka M; Hillebrand G; Dendorfer U; Krombach F; Kurrle R; Land W; Hammer C
    Transplant Proc; 1990 Aug; 22(4):1785-6. PubMed ID: 2143862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.